Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Contact us

• Submission enquiries: bmccancer@biomedcentral.com
• General enquiries: ORSupport@springernature.com